A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
NCT ID: NCT01541618
Last Updated: 2020-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
15 participants
OBSERVATIONAL
2012-01-31
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis
NCT01539395
Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment
NCT00942214
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
NCT05663853
Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab
NCT04964700
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tysabri Group
Patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
MSDX Complex-1 Biomarker test
MSDX Complex-1 Biomarker test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MSDX Complex-1 Biomarker test
MSDX Complex-1 Biomarker test
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age 45 years and older
3. Willing and able to provide written informed consent
4. Patient has high disease activity.
5. Patient is about to begin Natalizumab (Tysabri) therapy.
Exclusion Criteria
2. Known infectious or hematological disease.
3. Unwilling or unable to comply with the requirements of this protocol
4. Subject can not have a gadolinium enhanced MRI
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MSDx, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeannette Wendt, MD
Role: PRINCIPAL_INVESTIGATOR
Northwest NeuroSpecialists, PLLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northwest NeuroSpecialists, PLLC
Tucson, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MSDX-0411
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.